Teva strengthens biosimilars with FDA approval of PONLIMSI™ (denosumab-adet) for osteoporosis and cancer bone events, plus dual filing acceptance for Xolair® (omalizumab) biosimilar. Boosting affordability in biologics.
Written By: Adhithiyan J, BPharm
Reviewed By: Pharmacally Editorial Team
Teva Pharmaceutical Industries has recently strengthened its biosimilar portfolio through two significant regulatory developments: the U.S. FDA approval of PONLIMSI™ (denosumab-adet) and the acceptance of dual biosimilar filings referencing Xolair® (omalizumab). These milestones reflect Teva’s strategic expansion into biologics and biosimilars, a rapidly growing segment of the pharmaceutical industry.
PONLIMSI™, a biosimilar to denosumab, has been approved for indications related to bone health, including osteoporosis and prevention of skeletal-related events in patients with certain cancers. Denosumab works by inhibiting RANKL, thereby reducing bone resorption and improving bone strength. The approval by the U.S. Food and Drug Administration confirms that PONLIMSI meets the required standards of safety, efficacy, and quality comparable to the reference product.
In addition, Teva announced that its biosimilar candidate to Xolair® (omalizumab) has received dual regulatory filing acceptance. Omalizumab is widely used in the treatment of moderate-to-severe allergic asthma and chronic spontaneous urticaria. Dual filing acceptance indicates submissions across multiple indications or regions, highlighting Teva’s strategy to expand its global biosimilar footprint.
These developments are important in improving healthcare affordability. Biologic therapies are often expensive, limiting access for many patients. Biosimilars provide cost-effective alternatives while maintaining similar therapeutic outcomes, thereby increasing patient access and reducing the financial burden on healthcare systems.
However, biosimilar development is complex and challenging. It requires advanced manufacturing processes, strict regulatory compliance, and extensive comparability studies. In addition, market acceptance depends on physician confidence and patient awareness, which can influence adoption rates.
From a strategic perspective, Teva’s continued investment in biosimilars indicates a shift toward specialty and biologic medicines. This transition is essential for long-term growth as the global pharmaceutical market increasingly focuses on biologic therapies.
In conclusion, the FDA approval of PONLIMSI™ and the dual filing acceptance for the omalizumab biosimilar represent significant progress in Teva’s biosimilar pipeline. These advancements not only strengthen its market position but also contribute to making advanced therapies more accessible and affordable worldwide.
References
Teva Pharmaceutical Industries. Official Press Release on PONLIMSI™ Approval and Omalizumab Biosimilar Filing, 30 March 2026, Teva Pharmaceutical Industries Ltd. – Teva Gains Biosimilar Momentum with U.S. FDA Approval of PONLIMSI™ (denosumab-adet) and Dual Filing Acceptance for Biosimilar Candidate to Xolair® (omalizumab)
